Using in vivo scintigraphy with the 111In-labeled
somatostatin analog
octreotide,
tumor localizations were demonstrated in 11 of 17 patients (65%) with medullary
thyroid carcinoma (MTC).
Tumor localizations in the liver in 7 patients, and in the thyroid in 1 patient were not detected on
octreotide scintigraphy, most probably because of normal uptake of labeled
octreotide in these organs. Specific
somatostatin receptors were demonstrated in vitro on all 5 investigated
tumors which had also been visualized in vivo, as well as on 1
tumor that was not. Immunohistochemically,
somatostatin was present in 1 of 6
tumors that were visualized in vivo, and in neither of 2
tumors that were not. The ratio of serum
calcitonin over carcino-embryonic
antigen concentrations was significantly higher in patients whose MTCs were visualized during
octreotide scintigraphy than in those whose
tumors were not. We have formed the following conclusions: 1) In the majority of patients with metastatic MTC,
tumor sites can be visualized using
octreotide scintigraphy, although this technique is insensitive in detecting liver
metastases or intrathyroidal
tumor; 2) The visualization of MTC during in vivo
somatostatin receptor imaging correlates with the in vitro presence of
somatostatin receptors; 3) The immunohistochemical presence of
somatostatin in the
tumor does not seem to influence the outcome of in vivo
somatostatin receptor imaging; and 4) Higher serum
calcitonin over carcino-embryonic
antigen ratios in patients whose MTC is visualized during
octreotide scintigraphy might imply that
somatostatin receptors are present on more differentiated MTC.